Table 2 Univariate analysis for OS and PFS for patients with GEP-NET
5-year OSa (%) | P-valueb | 5-year PFSc (%) | P-value | |
|---|---|---|---|---|
All patients | 77.2 | N/A | 49 | N/A |
Sex | 0.48 | 0.65 | ||
Female | 78.9 | 52.7 | ||
Male | 75.5 | 46 | ||
Primary site | 0.26 | 0.11 | ||
Pancreas | 85.7 | 65.9 | ||
Non-pancreas | 72.8 | 40 | ||
WHO 2017 classification | < 0.001 | < 0.001 | ||
Well-differentiated, G1d | 90 | 68.9 | ||
Well-differentiated, G2 | 81.7 | 36.8 | ||
Well-differentiated, G3 | 25 | 0 | ||
Neuroendocrine carcinoma | 0 | 0 | ||
Ki-67 index | < 0.001 | < 0.001 | ||
≤ 2% | 92.2 | 64.4 | ||
3–20% | 77.3 | 37 | ||
> 20% | 14.6 | 0 | ||
Alkaline phosphatase | 0.14 | - | ||
Normal | 85.1 | - | ||
Elevated | 68.2 | - | ||
Primary management | 0.001 | 0.031 | ||
Surgery | 91.5 | 55.9 | ||
Medical | 48.7 | 29.4 | ||
Resection status | 0.002 | 0.08 | ||
Resection | 91.5% | 58.4% | ||
No resection | 50.7% | 34.6% |